Genprex News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

04.09.24	Genprex Plans To Launch New Subsidiary To Focus Gene Therapy To Treat Type-1, Type-2 Diabetes (RTTNews)
14.08.24	Genprex Stock Up On Positive Updates From Phase 1/2 Trials In Lung Cancer (RTTNews)
13.05.24	Genprex Appoints Toscano As Chairman (RTTNews)
03.04.24	Genprex Expands Trial Sites For Reqorsa Therapy-Tecentriq Trial In Small Cell Lung Cancer; Stock Up (RTTNews)
02.04.24	Genprex: Collaborators Report Positive Preclinical Data With NPRL2 Gene Therapy (RTTNews)
12.03.24	Genprex Granted Korean Patent For Reqorsa Therapy With Anti-PD-1, PD-L1 Antibodies (RTTNews)
07.02.24	Genprex To Expand Non-clinical Program To Study TUSC2, NPRL2 (RTTNews)
01.11.23	Genprex to Present at BIO-Europe 2023 Conference (PR Newswire)
20.10.23	Genprex to Host a Virtual Key Opinion Leader Event on "Bringing Gene Therapy to the Fight Against Lung Cancers" (PR Newswire)
04.10.23	Genprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire)
07.09.23	Genprex to Present at Upcoming September Investor Conference (PR Newswire)
22.08.23	Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs (PR Newswire)
10.08.23	Genprex Granted FDA Orphan Drug Designation (ODD) for REQORSA® Immunogene Therapy for the Treatment of Small Cell Lung Cancer (PR Newswire)
21.07.23	Genprex Announces Closing of $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire)
19.07.23	Genprex Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire)
18.07.23	Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh (PR Newswire)
05.07.23	Genprex Granted Chinese Patent for REQORSA® Immunogene Therapy in Combination with PD-1 Antibodies to Treat Cancers (PR Newswire)
28.06.23	Genprex Receives Third Fast Track Designation From FDA For REQORSA - Quick Facts (RTTNews)
28.06.23	Genprex Receives U.S. FDA Fast Track Designation for REQORSA® Immunogene Therapy in Combination with Tecentriq® for the Treatment of Small Cell Lung Cancer (PR Newswire)
30.05.23	Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer (PR Newswire)
25.05.23	Genprex Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating REQORSA® Immunogene Therapy in Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting (PR Newswire)
23.05.23	Genprex Unveils New Video Featuring Chief Medical Officer Discussing Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX® Nanoparticle Delivery System (PR Newswire)
08.05.23	Genprex to Participate and Present at Upcoming May Industry and Investor Conferences (PR Newswire)
19.04.23	Genprex Collaborators Report Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX® Nanoparticle Delivery System in Non-Small Cell Lung Cancer at the 2023 AACR Annual Meeting (PR Newswire)
18.04.23	Independent Researchers Find That TUSC2, the Gene Delivered by Genprex's REQORSA®, Functions as a Novel Tumor Suppressor for Glioblastoma (PR Newswire)
23.03.23	Genprex CEO Commends FDA's Initiative to Accelerate Approval Process for Gene Therapies (PR Newswire)
13.03.23	Genprex to Present at Bioprocessing Summit Conference (PR Newswire)
08.03.23	Genprex to Participate in March Investor and Industry Conferences (PR Newswire)
27.02.23	Genprex, Inc. Announces $4 Million Registered Direct Offering With a Single, Healthcare-Focused Institutional Investor (PR Newswire)
23.02.23	Genprex Announces Groundbreaking Data from Non-Human Primate Study Evaluating Novel Gene Therapy to Treat Type 1 Diabetes at 16th Annual International Conference on Advanced Technologies & Treatme... (PR Newswire)
05.01.23	Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh (PR Newswire)
04.01.23	Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies & Treatments for Diabetes (PR Newswire)
15.12.22	Genprex Strengthens Diabetes Gene Therapy Program with License of Additional Technology from University of Pittsburgh (PR Newswire)
14.12.22	Genprex Proceeds To Final Cohort In Phase 1 Trial Of REQORSA Combination In Lung Cancer (RTTNews)
14.12.22	Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer (PR Newswire)
02.12.22	Genprex to Present at Upcoming December Investor Conference (PR Newswire)
07.10.22	Genprex to Present at Upcoming October Investor and Industry Conferences (PR Newswire)
08.09.22	Genprex to Present at Upcoming September Investor Conference (PR Newswire)
16.08.22	Genprex Announces U.S. Patent for REQORSA™ Immunogene Therapy in Combination with Immune Checkpoint Inhibitors to Treat Cancers (PR Newswire)
15.08.22	Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer (PR Newswire)
13.07.22	Genprex to Participate in Next Generation Lipid-Based Nanoparticles Delivery Summit (PR Newswire)
02.06.22	Genprex to Present at Upcoming June Investor Conferences (PR Newswire)
19.05.22	Genprex to Present at Upcoming Investor Conference in May 2022 (PR Newswire)
09.05.22	Genprex's Chief Medical Officer to Be Featured as an Expert Panelist at the 33rd Annual Cancer Progress Conference (PR Newswire)
05.05.22	Genprex Issues Shareholder Letter and Provides 2022 Corporate Update (PR Newswire)
18.04.22	Genprex to Participate in Upcoming Investor and Industry Conferences in April 2022 (PR Newswire)
31.03.22	Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancer (Businesswire)
23.03.22	Genprex to Participate in Upcoming Investor Conference in March (Businesswire)
02.03.22	Genprex Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Genprex Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten